Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 5/2005

01-06-2005

Risk of non-Hodgkin lymphoma associated with occupational exposure to solvents, metals, organic dusts and PCBs (Australia)

Authors: Lin Fritschi, Geza Benke, Ann M. Hughes, Anne Kricker, Claire M. Vajdic, Andrew Grulich, Jennifer Turner, Samuel Milliken, John Kaldor, Bruce K. Armstrong

Published in: Cancer Causes & Control | Issue 5/2005

Login to get access
Metadata
Title
Risk of non-Hodgkin lymphoma associated with occupational exposure to solvents, metals, organic dusts and PCBs (Australia)
Authors
Lin Fritschi
Geza Benke
Ann M. Hughes
Anne Kricker
Claire M. Vajdic
Andrew Grulich
Jennifer Turner
Samuel Milliken
John Kaldor
Bruce K. Armstrong
Publication date
01-06-2005
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 5/2005
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-004-7845-0

Other articles of this Issue 5/2005

Cancer Causes & Control 5/2005 Go to the issue

OriginalPaper

Lifestyle factors and the risk of adult leukemia in Canada

OriginalPaper

Secular trends in the incidence, mortality, and survival rate of gastric cancer in a general Japanese population: the Hisayama study

OriginalPaper

Multiple primary cancers of separate organ sites: implications for research and cancer control (Australia)

OriginalPaper

Life After Cancer Epidemiology (LACE) Study: A cohort of early stage breast cancer survivors (United States)

OriginalPaper

Hormone replacement therapy is not associated with an increased risk of leukemia (United States)

OriginalPaper

Risk of non-small cell lung cancer and the cytochrome P4501A1 Ile462Val polymorphism
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits